IHS Chemical Week

People & Business :: M&A

Glaxo and Novartis announce major three-part business transaction

12:27 PM MDT | April 22, 2014 | Natasha Alperowicz

GlaxoSmithKline (GSK) today announced a major, three-part transaction with Novartis involving its consumer health-care, vaccines, and oncology businesses. GSK and Novartis, as part of the transaction, will create a new, world-leading consumer health-care business with 2013 pro forma revenues of £6.5 billion ($10.9 billion). GSK will have a 63.5% equity interest in the joint venture. Meanwhile, GSK will acquire Novartis’s global vaccines business, excluding influenza vaccines, for an initial cash consideration of $5.25 billion and subsequent potential...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa